Four things to know:
1. Dr. Klaas is a board-certified neurosurgeon from the University of Groningen in the Netherlands.
2. Oncopeptides focuses on the development of therapies for hematological cancers.
3. Dr. Klaas has a PhD in immune-hematology and has authored over 40 publications in international peer-reviewed journals.
4. He replaces Johan Harmenberg as CMO, who will remain as a member of the company’s medical team.
More articles on devices:
Dr. Adam Bruggeman: A spine surgeon’s most important OR trait and bundled benchmarks in spine
Optim Orthopedics welcomes Dr. Thomas Niemeier
7 hospitals expanding spine, neurosurgery programs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.